Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 4
1959 5
1960 40
1961 70
1962 90
1963 132
1964 134
1965 70
1966 60
1967 67
1968 79
1969 107
1970 107
1971 117
1972 130
1973 152
1974 145
1975 125
1976 142
1977 142
1978 122
1979 124
1980 112
1981 115
1982 90
1983 101
1984 122
1985 89
1986 92
1987 91
1988 94
1989 74
1990 92
1991 80
1992 85
1993 77
1994 103
1995 68
1996 68
1997 83
1998 92
1999 98
2000 157
2001 165
2002 197
2003 263
2004 238
2005 310
2006 275
2007 252
2008 239
2009 279
2010 286
2011 289
2012 327
2013 337
2014 295
2015 297
2016 342
2017 299
2018 305
2019 312
2020 333
2021 337
2022 290
2023 296
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

10,034 results

Results by year

Filters applied: . Clear all
Page 1
Spironolactone.
Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Carone L, et al. J Pain Symptom Manage. 2017 Feb;53(2):288-292. doi: 10.1016/j.jpainsymman.2016.12.320. Epub 2016 Dec 23. J Pain Symptom Manage. 2017. PMID: 28024992 Free article. Review.
A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Struthers A, Krum H, Williams GH. Struthers A, et al. Clin Cardiol. 2008 Apr;31(4):153-8. doi: 10.1002/clc.20324. Clin Cardiol. 2008. PMID: 18404673 Free PMC article. Review.
This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and eplerenone. A Medline search identified clinical studies assessing spironolactone and eplerenone. Priority was given to large, well-co …
This article reviews the pharmacology, clinical efficacy, and tolerability of the two available blocking agents, spironolactone and e …
Spironolactone for hypertension.
Batterink J, Stabler SN, Tejani AM, Fowkes CT. Batterink J, et al. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008169. doi: 10.1002/14651858.CD008169.pub2. Cochrane Database Syst Rev. 2010. PMID: 20687095 Review.
BACKGROUND: Spironolactone is an aldosterone antagonist, considered fourth line therapy for hypertension in patients already treated with multiple medications. OBJECTIVES: Primary: to determine the effect of spironolactone on patient mortality, morbidity, and to qua …
BACKGROUND: Spironolactone is an aldosterone antagonist, considered fourth line therapy for hypertension in patients already treated …
Spironolactone.
Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Ochs HR, et al. Am Heart J. 1978 Sep;96(3):389-400. doi: 10.1016/0002-8703(78)90052-2. Am Heart J. 1978. PMID: 356569 Review. No abstract available.
Spironolactone.
Danby FW. Danby FW. J Am Acad Dermatol. 1992 Jan;26(1):137. doi: 10.1016/s0190-9622(08)80534-8. J Am Acad Dermatol. 1992. PMID: 1580900 No abstract available.
Spironolactone: a re-examination.
Skluth HA, Gums JG. Skluth HA, et al. DICP. 1990 Jan;24(1):52-9. doi: 10.1177/106002809002400112. DICP. 1990. PMID: 2405587 Review.
A review of the aldosterone antagonist spironolactone is presented. It is effective both as monotherapy and in combination with other hypotensive agents in the control of both essential and hyperaldosterone-induced hypertension. It is useful as a diuretic in conditions suc …
A review of the aldosterone antagonist spironolactone is presented. It is effective both as monotherapy and in combination with other …
Antimineralocorticoids.
Agarwal MK, Lazar G. Agarwal MK, et al. Ren Physiol Biochem. 1991 Nov-Dec;14(6):217-23. doi: 10.1159/000173409. Ren Physiol Biochem. 1991. PMID: 1720252 Review.
A number of chemical modifications in the spironolactone molecule were attempted over the last decade to synthesize ligands with high affinity for the mineralocorticoid receptor (MCR), and for possible use in the clinical control of the hypertensive disease. ...None of the …
A number of chemical modifications in the spironolactone molecule were attempted over the last decade to synthesize ligands with high …
Hyperaldosteronism.
Tidd MJ. Tidd MJ. Br Med J. 1969 Oct 4;4(5674):52-3. doi: 10.1136/bmj.4.5674.52-c. Br Med J. 1969. PMID: 5822099 Free PMC article. No abstract available.
10,034 results
You have reached the last available page of results. Please see the User Guide for more information.